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Abstract
Renal cell carcinoma accounts for about 2% of all adult malignancies. More than 300,000 
individuals are affected each year. Unfortunately, around 30% of cases are discovered 
in advanced stages. Surgical resection remains the mainstay of treatment for localized 
disease and relapses can reach up to 40% in some cases. The effective treatment of 
metastatic RCC with systemic targeted therapy gives a strong rationale for its use as 
adjuvant treatment in high-risk patients. This chapter reviews different modalities that 
have been used as an adjuvant therapy for nonmetastatic renal cancer. Clinical trials 
using targeted therapy are discussed in detail, as they are becoming options for treat-
ment in high-risk patients. While the current set of completed adjuvant clinical trials 
have provided conflicting results, there are additional large-scale trials that are still in 
progress. Future directions include—incorporating a genetic recurrence score to evalu-
ate risk of relapse in patients, developing an adequate and an objective standardized 
adjuvant trial design, identifying novel biomarkers, and evaluating novel drug targets. 
Based upon current clinical trial evidence, motivated high-risk patients should have 
a discussion with the urology oncology team regarding the benefits of adjuvant TKI 
sunitinib or consider enrollment in current ongoing immuno-oncology (IO) adjuvant 
clinical trials.
Keywords: renal cell carcinoma, adjuvant treatment for RCC, treatment of high-risk 
RCC, targeted therapy as adjuvant
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1. Introduction
Every year, approximately 338,000 individuals are diagnosed with kidney cancer globally, 
representing about 2% of all cancers [1]. Renal cell carcinoma (RCC) accounts for approxi-
mately 90% of all kidney cancers—affecting an estimated 300,000 people each year [2, 3]. 
Approximately 30% of kidney cancer patients represent an advanced disease stage at diagno-
sis, with an average 5-year survival rate of approximately 16% [4, 5].
The management of RCC, regardless of its histological subtype or stage, involves surgical 
resection of the tumor through either a radical or partial nephrectomy [6]. While surgery is 
not curative in cases involving metastatic disease, with localized RCC, surgical intervention is 
considered the optimal standard of care [6, 7].
But despite that, postsurgical recurrence of cancer is a prevalent issue in cases of localized RCC 
(stage 2 or 3 disease) with a 5-year relapse rate of 30–40% and, as such, surgery is insufficient for 
long-term disease free survival [8, 9]. Hence, even though the current standard for postoperative 
care continues to be radiographic surveillance, the need for effective adjuvant therapy for local-
ized high risk for recurrence RCC would be helpful and desired by the surgical community [8–10].
In view of these findings and the effective treatment of metastatic RCC with Immunotherapy 
in the 1990s or more recently with targeted therapy, a strong rationale for systemic adjuvant 
therapy exists in high risk for recurrence patients.
In this chapter, we review different treatment modalities have been used as an adjuvant ther-
apy for nonmetastatic renal cancer postsurgical resection with emphasis on targeted therapy 
as becoming an option to offer patients.
2. Stratifying risk of recurrence
A critical element in both the testing and effective clinical use of adjuvant therapy involves 
determining whether there is a high risk of disease recurrence post nephrectomy and accord-
ingly identifying patients that are most likely to benefit from the therapy. As discussed earlier, 
the determination of recurrence risk is currently nonstandardized in adjuvant therapy testing. 
Several models and clinical nomograms have been developed to predict the risk of disease recur-
rence and progression, as well as evaluate additional oncological endpoints [11–19]. Examples 
of some validated models include the Cindolo Recurrence Risk Formula, Leibovich scoring sys-
tem, Karakiewicz scoring system, Kattan nomogram, Mayo Clinic stage, size, grade, and necrosis 
scoring system (SSIGN), and the University of California Los Angeles Integrated Staging System 
(UISS) [11–19] (Tables 1 and 2). These systems usually incorporate information regarding differ-
ent variables and various prognostic signs and indictors such as tumor size, stage and character-
istics, clinical risk factors, and various other pathological features and signs for a relatively robust 
evaluation [11–21]. Among these models, the UISS, Kattan and SSIGN nomograms have shown 
relatively better discriminative accuracy in some comparative studies and hence are most com-
monly utilized [13, 22, 23].
In terms of a general approximation, recurrence risk can be segregated into three broad catego-
ries based on the UISS nomogram: low, intermediate and high risk [18]. These three risk groups 
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are differentiated based on the probability of survival and disease recurrence and patients, in 
a clinical setting, can be stratified through an independent clinical assessment of UISS compo-
nents, such as tumor stage, grade, and other pathophysiological characteristics [18, 19]. While the 
UISS components have not been formally validated as independent recurrence risk prediction 
models, they are important prognostic indicators for various oncological outcomes and end-
points that are invariably linked with the risk of disease relapse [18, 19]. As such, an evaluation 
of tumor characteristics—particularly tumor stage—can serve as a rough guide for preliminary 
differentiation between high, intermediate and low risk categories in the clinical setting. [24–27] 
This correlation has been supported by independent studies which have reported higher recur-
rence free survival (RFS) rates for smaller, T1a-T1b stage tumors and lower RFS rates for larger, 
T3-T4 stage tumors [24–27]. Thus, patients with T1a-T2a tumors can be estimated to have lower 
recurrence risk while those with T3b-T4 tumors can be placed into the high-risk category [24–27]. 
Among these varying risk levels, currently only those who present a high risk of disease recur-
rence can potentially benefit from adjuvant therapy postsurgical resection of the tumor.
The incorporation of biotechnology and an improved understanding of genetic and molecular 
markers may potentially lead to the next major advancement in improving the predictive 
accuracy of relapse risk. Recent studies have reported the development of novel gene assays 
Characteristics Points
Tumor pT1a 0
pT1b 2
pT2 3
pT3-pT4 4
Dimension <10 cm 0
>10 cm 1
Fuhrman 1–2 0
3 1
4 3
Tumor necrosis Absent 0
Present 1
Lymph nodes pNx/pN0 0
pN1-pN2 2
Table 1. Leibovich prognosis score.
T stage 1 2 3 4
Furman grade 1–2 3–4 1–4 1 2–4 1–4
ECOG PS 0 >1 any >1 any 0 >1 0 >1 any
Risk group Low Intermediate High
Table 2. UISS prognosis score.
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and have further elucidated several new biomarkers [28–31]. Nonetheless, further investiga-
tion, testing and development is required before molecular approaches can be incorporated 
for clinical application in an efficient and economically viable manner.
3. Immunotherapy IL2,IFα
Two trials that used adjuvant IFN-α [32, 33] and one study that used adjuvant high-dose 
IL-2 (82) were negative for any benefit. The latter study was designed and powered to show 
an improvement in predicted 2-year DFS from 40% for the observation group to 70% for the 
treatment group. Despite full accrual 30% improvement in 2-year DFS could not be achieved 
which lead to early study closure.
Combination treatment with IFN-α and IL2 also failed to improve DFS in one trial [34].
The combination of cytokines with 5-fluorouracil (5-FU) also failed to improve DFS in the 
adjuvant setting [35, 36].
In one randomized adjuvant trial, triple combination therapy using IL-2, IFN-α, and5-FU was 
associated with significant toxicity which leads to 35% of the patients did not complete the 
study and also resulted in no benefit in DFS or OS [37].
4. Tumor vaccines
Autologous irradiated tumor cells mixed with bacillus Calmette-Guérin (BCG) were tested in 
two randomized trials and did not result in prolonged DFS [38–40].
Similarly, autologous, tumor-derived heat-shock protein (glycoprotein 96)-peptide complex 
(HSPPC-96; vitespen) did not result in a statistically significant improvement of DFS [41].
A trial with an autologous renal tumor cell vaccine only reported improved DFS in the vac-
cine group [42], but the number of patients lost after the randomization step, the imbalance of 
this loss, and the absence of tabulation of OS led to criticism of the results [43].
This therapy has not been implemented in routine clinical practice.
5. Hormonal therapy
The occasional response of patients with metastatic RCC to hormonal therapy with medroxy-
progestrone acetate (MPA) provided a rationale in trying it in adjuvant sitting.
In a prospective randomized trial of adjuvant MPA after radical nephrectomy, 136 patients 
received either MPA 500 g (three times a week) for 1 year or observation. With a median follow 
up of 5 years. There were no significant differences in relapses between the adjuvant group and 
the observation group (32.7 vs. 33.9%, respectively) [44].
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6. Radiotherapy
Radiotherapy has been used for symptoms palliation in metastatic RCC like hematuria and 
painful bone metastasis. Also, long-term PFS has been reported for in a subset of patients 
following radiotherapy for solitary bone metastases [31].
One prospective, randomized study in 72 patients comparing administration of radiation of 
the kidney bed, and ipsilateral and contralateral lymph nodes for stages II and III RCC versus 
observation reported relapse rates of 48% in both groups. Forty-four percent of patients in 
the radiotherapy arm had significant complications that contributed to the death of 19% of 
patients [45–47].
7. Adjuvant therapy in the era of the new targeted therapy
7.1. Targeted therapy
Systemic therapy for mRCC has particularly changed over the last decade with the introduc-
tion of targeted therapy and the evolvement of tyrosine kinase inhibitors (TKI) [7, 49–53]. 
This development has directly resulted from an improved understanding of the pathogenesis 
and molecular biology of RCC [49–54]. TKIs have provided a novel therapeutic approach for 
better managing the pathology through the inhibition of targets such as the mammalian target 
of rapamycin (mTOR) pathway and the vascular endothelial growth factor receptor (VEGFR), 
which consequently help inhibit processes that are critical for cancer progression [7, 49–53]. 
Particularly in cases of metastatic RCC, these inhibitors have been effective in increasing the 
overall survival and response rates than previously used immunotherapy and chemotherapy 
agents [7, 49–53].
Seven drugs are now approved for targeted therapy, and several others are being evaluated in 
clinical trials [50–53, 55]. At the molecular level, the mechanism of these drugs involves inter-
rupting the molecular signal transduction of various signaling pathways which then ultimately 
affects pathogenic factors like tumor vascularity, growth and progression [50–53, 55]. Sunitinib 
and Pazopanib are currently the accepted standard of care for the management of metastatic 
RCC and are the most widely used first line agent due to their robust clinical efficacy and 
established toxicity profile [50–53, 55]. The current set of therapeutic agents used in targeted 
therapy exploit the Von Hippel-Lindau (VHL) and hypoxia-inducible factor (HIF) pathway 
associated with clear cell RCC pathogenesis [56, 57].
7.2. VHL-HIF pathway
Clear Cell RCC (ccRCC) normally entails a biallelic inactivation of the VHL tumor suppressor 
gene at the 3p25-26 locus. VHL inactivation, which occurs due to factors such as mutation, 
hyper-methylation, or deletions, results in the formation of defective pVHL protein—ulti-
mately leading to the activation and upregulation of HIF-1α [56, 57]. Activated HIF protein 
serves as a transcription factor for various pro-tumorigenic target genes such as vascular 
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endothelial growth factor (VEGF), transforming growth factor-α and platelet-derived growth 
factor (PDGF) that are involved in pathogenic processes like angiogenesis, tumor cell prolif-
eration and cell survival. [56, 57] Apart from this central pathway, the mTOR pathway also 
intersects with HIF pathway upstream of the VHL gene and hence also plays a critical role in 
influencing HIF process and function. [56, 57] Thus, inhibiting different targets in this path-
way has yielded favorable results in mRCC cases [50–53, 55–57]. Given the success of targeted 
therapy agents in the metastatic setting, recent efforts have been focused into translating this 
into the adjuvant setting.
7.3. Clinical trials: targeted therapy in adjuvant setting
The contemporary endeavors to transpose targeted therapy in the adjuvant setting have been 
inspired by the increased clinical knowledge gained through the development and evaluation 
of interventions for stage IV disease [9, 10, 58, 59]. There are currently seven multicenter, 
double-blind, placebo-controlled, randomized adjuvant clinical trials, involving targeted 
therapy agents [9, 10, 58, 59]. Five of these trials involve tyrosine kinase inhibitors, while one 
involves an mTOR inhibitor and the other a monoclonal chimeric antibody [9, 10, 58–63]. So 
far, four of these trials have been completed including the, ARISER, ASSURE, S-TRAC and 
PROTECT trials while the other ones are still in progress [60–63].
7.3.1. ARISER trial
This ARISER trial, completed in 2014, evaluated the efficacy of girentuximab [60], a mono-
clonal antibody to carbonic anhydrase IX (a HIF downstream target gene), in the adjuvant 
setting for intermediate to high risk for recurrence patients. This multicenter, phase III trial 
involved 864 patients with resected clear cell tumors, who were randomized to receive either 
girentuximab or placebo, once a week, for 24 weeks. Girentuximab recipients received a 
50 mg dose during the first week followed by a weekly dose of 20 mg for the next 23 weeks. 
The median disease free survival (DFS) duration for the participants in the intervention arm 
was 71.4 months (HR: 0.97; 95% CI, 0.79–1.18) while the endpoint was never reached for 
the placebo group. As such, the study indicated no interventional advantage but it recom-
mended further investigation of adjuvant girentuximab in patients with high levels of CAIX 
in affected renal tissue.
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7.3.2. ASSURE trial
The ASSURE trial, completed in 2016, was a randomized, double-blind, placebo-controlled, 
phase 3 clinical trial in which 1943 patients from 226 study centers in North America were 
assigned to one of three intervention arms—sunitinib, sorafenib or placebo in intermediate to 
high-risk patients [61]. Sunitinib patients received 50 mg for 54 weeks on a 4 of 6 week cycle; 
sorafenib recipients received 400 mg twice per day throughout each cycle, and placebo recipi-
ents were randomly assigned either the sunitinib placebo or the sorafenib placebo. The inter-
ventions were evaluated using DFS as the primary endpoint. Trial results indicated that the 
median DFS duration was approximately 5.8 years for sunitinib [HR: 1.02; 97.5% CI: 0.85–1.23; 
P = 0.8038], 6.1 years for sorafenib (HR: 0.97; 97.5% CI: 0.80–1.17; P = 0.7184), and 6.6 years for 
placebo—hence suggesting no survival benefit from the interventions relative to the placebo. 
Instead, the results further reported detrimental effects due to the increased toxicity of the treat-
ment despite the dose reductions—suggesting no benefit of the particular TKI in the adjuvant 
setting. Of note, this trial had a higher number of TKI dose reductions (potentially suggesting 
suboptimal drug dosing) and more intermediate risk for recurrence patients than other trials.
7.3.3. S-TRAC trial
The S-TRAC study, also completed in 2016, was a prospective, randomized, double-blind, 
phase 3 clinical trial involving 615 patients from 21 countries [62]. Of the 615 patients who 
underwent randomization, 309 were assigned to the sunitinib arm and 306 to the placebo arm. 
These patients were all “high risk of recurrence.” Sunitinib recipients received 50 mg for a 
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year on a 4 of 6 week cycle. The interventions were evaluated by comparing DFS, the primary 
endpoint of the study, between the two trial arms. The study results indicated that the median 
DFS duration was 6.8 years (95% CI: 5.8 to not reached) in the sunitinib group and 5.6 years 
(95% CI: 3.8–6.6) in the placebo group (HR: 0.76; 95% CI: 0.59–0.98; P = 0.03). The adverse effects 
observed in sunitinib recipients were consistent with its known toxicity profile. As such, the 
results from this trial support the potential for sunitinib as a treatment option in the adjuvant 
setting with a DFS advantage. However, overall survival endpoints have not yet been reported.
7.3.4. PROTECT trial
The PROTECT study, completed recently in 2017, was a phase 3 randomized clinical trial 
that evaluated the efficacy of adjuvant pazopanib as compared to placebo in preventing RCC 
recurrence in intermediate to high-risk patients [63]. The trial enrolled 1538 participants and 
the majority of the pazopanib recipients received a revised dosage of 600 mg, daily for a year, 
following a dose reduction from 800 mg which caused severe side effects. The interventions 
were evaluated by comparing DFS as the primary endpoint measure between the two trial 
arms. The study did not meet its primary endpoint and indicated no significant benefit of 
pazopanib-600 mg in prolonging DFS as compared to placebo (HR: 0.86; 95% CI, 0.70–1.06; 
P = 0.165). However, a subgroup analysis of pazopanib-800 mg recipients indicated a 31% 
decline in DFS (HR, 0.69; 95% CI, 0.51–0.94; P = 0.02). While the DFS results were conflicting 
between the 600 mg and 800 mg groups, the study reported similar adverse event profiles 
between both the groups.
7.3.5. Comparison of current adjuvant trial design
The differing outcomes that have been indicated in the current set of completed trials may be 
accounted for by the distinct sample groups, dose regimens, risk assessment criteria and trial 
methods [60–63]. This collectively represents a fundamental limitation that underscores all 
current adjuvant clinical trials. First, the patient inclusion criteria characteristically differ, in 
multiple ways, across all adjuvant trials [60–63]. For example, in the S-TRAC trial, the selected 
sample exclusively included patients with late-stage, loco-regional, clear-cell RCC while other 
trials such as the ASSURE, ARTISER and PROTECT trials used a less restricted criteria and 
included patients with stage 1 or stage 2 tumors and non-clear-cell histologies [60–63]. In 
addition, another major cause of heterogeneity lies in the risk assessment and stratification 
criteria as the scoring system used in the current set of adjuvant trials are not standardized, 
and hence this invariably contributes to a varied assessment of recurrence risk [60–63]. With 
respect to the conflicting sunitinib trials (S-TRAC vs. ASSURE), additional sources of variation 
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that might have led to inconsistent outcomes include varying dose regimens, specifically with 
respect to the midtrial dose reductions for sunitinib, as well as differing trial criteria for estab-
lishing disease status and assessing primary end point status [61, 62, 64].
7.4. Targeted immunomodulatory therapy
The development of therapy that targets oncogenic signaling pathways has advanced the 
treatment landscape for patients with advanced renal cell carcinoma. While nonspecific 
immunotherapy with IL-2 and IFN-α was the former mainstay in the management of meta-
static disease, there was a shift away from it with the advent of targeted therapy which yielded 
relatively better response rates [32–34, 48–54, 65–68]. However, over the last couple of years, 
cancer immunotherapy has been revisited and, as a result, targeted immunomodulatory 
therapy, involving novel immunomodulating agents, has been reincorporated in combina-
tion therapy regimes for mRCC management—hence allowing for an induced immuonologic 
effect in addition to the inhibitory effect on tumor biology and microenvironment [69, 70]. 
This has been inspired in part by disease resistance that is progressively manifesting itself 
against standard targeted therapy in the landscape of metastatic disease management [69, 70].
Given that multiple mechanisms are employed by tumors to evade and suppress the immune 
system, research toward better understanding those mechanisms of immunomodulation has 
been critical in informing the therapeutic landscape [69, 71]. Particularly, an improved under-
standing of the factors regulating the antitumor immune response has led to the development 
a novel form of cancer immunotherapy involving checkpoint inhibitors and other immune 
therapies such as T-cell agonists, adoptive T-cell therapies and novel vaccines which are being 
evaluated across different trials for metastatic RCC [69, 71].
7.5. Immune checkpoint inhibitors
Immune checkpoints serve a critical protective function of preventing immune response 
against host cells through a series of complex interactions [71–73]. However, investigation 
into the pathogenic mechanisms of RCC revealed that cancer cells can induce similar interac-
tions with host checkpoint receptors and can hence suppress the human immune response 
[71–73]. Immune checkpoint inhibitors counter these molecular mechanisms through which 
tumor cells evade immune recognition [71–73].
Programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated antigen 4 
(CTLA-4) are currently the most well understood inhibitory checkpoint receptors [71–73]. 
The PD-1/PD-L1 axis involves an inhibitory interaction between a T-cell inhibitory ligand 
PD-L1, expressed on tumor cell surface, and a PD-1 receptor on the lymphocyte [71–73]. 
Hence, mimicking this interaction ultimately allows tumor cells to evade the adaptive 
immune response through suppression of T-cell function. The CTLA-4 pathway is similarly 
exploited by tumor cells [71–73]. During an adaptive immune response, immune activation 
occurs through an interaction between the T-cell receptor (TCR) and the antigen-presenting 
cell (APC) along with the co-stimulation of CD28 on the T cell [71–73]. This activation is 
negatively regulated by an inhibitory interaction between CTLA-4 and its ligands—CD80 or 
CD86 [71–73]. Thus, the targeted inhibition of these checkpoint receptors through targeted 
antibodies, in both the pathways mentioned above, could allow for T-cell activation and 
effective immune function [71–73].
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The first checkpoint inhibitor which demonstrated a survival benefit in patients with metastatic 
RCC was nivolumab—an anti-PD1 monoclonal antibody [74]. The inhibitor, which received 
FDA approval in 2015 based on the results from a trial evaluating nivolumab versus everoli-
mus, is effective in yielding positive response rates when used for treatment of advanced RCC 
in patients who have undergone prior anti-angiogenic therapy [74]. Apart from nivolumab, 
multiple other checkpoint inhibitors are being currently evaluated in different trials against 
advanced RCC [71–73].
7.6. Immunomodulatory therapy in the adjuvant setting
Given their recent development, many immune checkpoint inhibitors are still being evaluated 
for their efficacy and toxicity against metastatic RCC, and hence investigation of these inhibi-
tors in the adjuvant setting has been limited. Currently, there are a few ongoing clinical trials 
that are evaluating different checkpoint inhibitors in both the adjuvant setting as well as the 
neo-adjuvant (presurgery) setting (Table 3) [75–78].
The IMmotion, KEYNOTE-564, and CheckMate 914 are phase III trials evaluating the efficacy 
and safety of adjuvant atezolizumab, pembrolizumab, and nivolumab/ipilimumab (combi-
national regimen) respectively in prolonging the DFS of RCC patients who are at high risk 
of disease recurrence post nephrectomy [75, 77, 78]. In addition to the adjuvant trials, an 
ongoing study in the neo-adjuvant setting includes the PROSPER trial which is evaluating the 
efficacy of pre-nephrectomy nivolumab [75]. These trials, which have either started already 
or are expected to begin later this year, are currently in their recruitment or pre-recruitment 
phases and are anticipated to be completed by 2022–2024. [75, 77, 78] Apart from these clinical 
Adjuvant clinical trials in RCC using immune therapies
Authors Intervention Patient population Design No. of 
patients
Outcome
Pizzocarro et al. 
[32]
IFN-α2b vs. 
placebo
Robson stages II 
and III (T3aN0M0 
and T3bN0M0 or 
T2/3N1-3M0)
Multicenter, 
randomized, 
controlled trial
247 5-year OS: 0.665 
(control) vs. 0.660 
(treatment) (HR 
1.040; 95% CI, 
0.671–1.613, P ¼ 
_0.861)
5-year DFS: 0.671 
(control) vs. 0.567 
(treatment) (HR 
1.412; 95% CI, 
0.927–2.149, P ¼ 
_0.107)
Passalacqua 
et al. [34]
IL-2 and IFN-α _v 
observation
pT1, T2, T3 a-b-c; 
pN0-pN3,M0M
Multicenter, 
randomized, 
controlled trial
310 5-year DFS: 0.73 
(control) vs. 0.73 
(treatment)
10-year DFS: 0.60 
(control) vs. 0.73 
(treatment) (HR 
0.84; 95% CI, 
0.54–1.33, P ¼ _0.47)
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Adjuvant clinical trials in RCC using immune therapies
Authors Intervention Patient population Design No. of 
patients
Outcome
Clark et al. [48] IL-2 vs. observation T3b-4 or N1-3 (LA) 
or M1
Multicenter, 
randomized, 
controlled trial
69 total; 
44 LA, 
25M1 
disease
2-year DFS: 48% 
(control in LA 
patients) vs. 53% 
(treatment in LA 
patients) (P ¼ _0.73)
2-year OS: 77% 
(control in LA 
patients) vs. 86%
Messing et al. 
[33]
IFN-α-NL vs. 
observation
pT3–4a and/or 
node-positive
Multicenter, 
randomized, 
controlled trial
283 At 10.4 years median 
follow-up: Median 
survival: 7.4 years 
(control) vs. 5.1 years 
(treatment) (P ¼ 
_0.09). DFS: 3.0 years 
(control) vs. 2.2 years 
(treatment) (P ¼ 
_0.33)
Atzpodien et al. 
[35]
IL-2 and IFN-α2a 
and intravenous 5 
vs. fluorouracil
pT3b/c pN0 or 
pT4pN0), pN, complete 
resection of tumor 
relapse or solitary 
metastasis (R0)
Multicenter, 
randomized, 
controlled trial
203 At median follow-up 
of 4.3 years:
2-year OS: 91% 
(control) vs. 81% 
(treatment)
5-year OS: 76% 
(control) vs. 58% 
(treatment)
8-year OS: 66% 
(control) vs. 58% 
(treatment) (P ¼ 
_0.0278)
2-year DFS: 62% 
(control) vs. 54% 
(treatment)
5-year DFS: 49% 
(control) vs. 42% 
(treatment)
8-year DFS: 49% 
(control) vs. 39% 
(treatment) (P ¼ 
_0.2398)
Aitchison et al. 
[36]
IL-2 and IFN-α2a 
and intravenous 
5-fluorouracil
T3b-c,T4 or any pT and 
pN1 or pN2 or positive 
microscopic margins or 
microscopic vascular 
invasion
Multicenter, 
randomized, 
controlled trial
309 3-year DFS: 50% 
(control) vs. 60% 
(treatment) (HR 
0.87; 95% CI, 
0.63–1.20)
5-year OS: 60% 
(control) vs. 68% 
(treatment) (HR 
0.91; 95% CI, 
0.60–1.38)
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studies, there are several checkpoint inhibitors that are in development as well as others that 
are currently being evaluated in trials for mRCC and would subsequently be assessed in the 
adjuvant setting [71–73] (Tables 4–6).
7.7. Change of practice
The European Association of Urology Renal Cell Cancer Guidelines Panel, which includes 
patient representatives and clinicians, considered a number of different scenarios to determine 
what would be required from S-TRAC to change practice. The decision on practice change 
Adjuvant clinical trials in RCC using immune therapies
Authors Intervention Patient population Design No. of 
patients
Outcome
Galligioni et al. 
[39]
Autologous 
irradiated tumor 
cells and BCG vs. 
observation
Stages I, II, and III Prospective, 
randomized, 
controlled trial
120 At 61 months 
median follow-up:
5-year OS: 78% 
(control) vs. 69% 
(treatment)
5-year DFS: 72% 
(control) vs. 63% 
(treatment)
Adler et al. [40] Autologous 
irradiated tumor 
cells & BCG & 
hormone vs. 
hormone
All stages Prospective, 
randomized, 
controlled trial
43 Trend for 
prolongation of DFS 
for stage I, II, and III 
(P o.1)
Wood et al. [41] Autologous, 
tumor-derived 
heat-shock protein 
(glycoprotein 
96)-peptide 
complex (HSPPC-
96; vitespen) vs. 
observation
cT1b–T4 N0 M0, 
or cTanyN1-
2M0Multicenter
Multicenter, 
randomized, 
controlled trial
819 At 1.9 years 
median follow-up: 
recurrence: 39.8% 
(control) vs. 37.7% 
(treatment) (HR 
0.923; 95% CI, 
0.729–1.169, P ¼ 
_0.506) OS not 
mature
Jocham et al. 
[42]
Autologous 
renal tumor cells 
(Reniale)
pT2–3b pN0–3 Multicenter, 
randomized, 
controlled trial
558 At 5-year follow-up: 
DFS: 67.8% 
(control) vs. 77.4% 
(treatment) (P 
¼ _0.0204). At 
70-month follow-up: 
DFS: 59.3% (control) 
vs. 72% (treatment). 
HR for tumor 
progression: 1.58 
(95% CI 1.05–2.37) 
and 1.59 (1.07–2.36) 
(P ¼ _0.0204)
IFN, interferon; IL, interleukin; NL, neutral lymphoblastoid; LA, locally advanced; BCG, bacillus Calmette-Guérin; 
CI, confidence interval; LA, locally advanced; HR, hazard ratio; M, metastatic; OS, overall survival; DFS, disease-free 
survival.
Table 3. Adjuvant clinical trials in RCC using immune therapies.
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was taken in the context of the data from ASSURE. Results showed that only 1 out of 15 (6%) 
of the panel would change their standard of care when considering the DFS and OS closest 
to S-TRAC (DFS: HR 0.75, p < 0.05; OS: HR 1.0, p > 0.05). Standard practice would only be 
significantly influenced by a significant survival benefit. In addition, kidney cancer patients 
from the International Kidney Cancer Coalition (IKCC) participated in a questionnaire about 
Trial name. Trial ID Intervention Sample 
size
Inclusion criteria 
(histology; stage/
grade)
Primary 
endpoint 
measure
Completion 
date
ARISER NCT00087022 Girentuximab 864 ccRCC; T1b,N0, 
NX,MO, 
T2,N0, NX,MO 
(grade ≥ 3) (risk: 
intermediate-
High)
DFS,OS 2014
ASSURE NCT00326898 Sorafenib or 
Sunitinib
1943 Any; pT1bN0M0 
(grades 3–4), pT2-
4N1-3M0 (risk: 
intermediate-high)
DFS 2016
S-TRAC NCT00375674 Sunitinib 615 ccRCC; pT2N0M0 
(grades 3–4) or 
pT3-4N0M0 or 
pTxN1M0 (risk: 
High)
DFS 2016
PROTECT NCT01235962 Pazopanib 1500 ccRCC; pT2N0M0 
(grades 3–4) or 
pT3-4N0M0 or 
pTxN1M0 (risk: 
intermediate-high)
DFS 2017
Table 4. RCC adjuvant clinical trials that have been completed.
Trial name. Trial ID Intervention Sample 
size
Inclusion criteria 
(histology; stage/
grade)
Primary 
endpoint 
measure
Estimated 
completion 
date
SORCE NCT00492258 Sorafenib 1420 Any; pT1a N0M0 
(grade 4), pT1b 
N0M0 (grades 
3–4), pT2-4N0M0, 
pT1b-4N1M (risk: 
intermediate-high)
DFS 2019
ATLAS NCT01599754 Axitinib 592 ccRCC; pT2-
4N0M0 or 
pTxN1M0 (risk: 
high)
DFS 2019
EVEREST NCT01120249 Everolimus 1218 Any; pT1bN0M0 
(grades 
3–4) or pT2-
4N1-3M0 (risk: 
intermediate-high)
DFS 2021
Table 5. Current set of adjuvant clinical trials that are still in progress.
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the implications for STRAC. The results lacked clarity. Twenty-two patient representatives 
from the IKCC network were asked what degree of PFS advantage would be needed to justify 
taking sunitinib for 1 year. Approximately one-third of patients favored not taking sunitinib 
when faced with the S-TRAC results [79].
Recently, on November 2017, the FDA approved the use sunitinib for the adjuvant treatment 
of adult patients at high risk of recurrent renal cell carcinoma following nephrectomy. The 
approval was based on (S-TRAC) trail.
8. Conclusions and future directions
Targeted therapy has become the current mainstay in the management of metastatic RCC 
and its success with advanced stage disease has been the driving force behind the increas-
ing number of targeted therapy trials in the adjuvant setting. The emergence of immune 
checkpoint inhibitors in the last couple of years has further led to important advances in 
our understanding and management of mRCC. However, many ongoing trials are yet to be 
completed in both cases and there is ample potential for further investigation—especially 
with respect to combinational therapy regimes. This includes the combination of TKIs with 
immune therapies (e.g., NCT01513187: Pazopanib with Interferon Alfa 2-A), combination 
of TKIs with chemotherapeutics (e.g., NCT00556049: Sunitinib with Gemcitabine), and the 
combination of anti-VEGF antibodies and mTOR inhibitors (e.g., NCT01399918: bevacizumab 
and everolimus). All of these treatments may be of interest for future adjuvant trials in RCC if 
they are found to be effective in stage IV disease. However, they may have more side effects, 
making them less suitable in particular for adjuvant treatment. Nonetheless, the current infor-
mation, which has resulted from all the progress in the field, remains incongruent. While the 
current set of completed adjuvant clinical trials have provided negative or conflicting results 
(ARISER, PROTECT, S-TRAC vs. ASSURE), there are additional large-scale trials that are still 
in progress. The existing trial design has several limitations, the key one being the overall 
lack of standardization seen across various assessment criteria. Future directions include 
Trial name Trial ID Intervention Estimated 
enrollment
Primary 
endpoint 
measure
Start date Completion 
date
PROSPER NCT03055013 Nivolumab 
(pre-Nx)
766 DFS February 
2, 2017
2022
KEYNOTE-564 NCT03142334 Pembrolizumab 950 DFS June 9, 
2017
2022
CheckMate 914 NCT03138512 Nivolumab, 
ipilimumab
800 DFS July 3, 
2017
2023
IMmotion010 NCT03024996 Atezolizumab 664 DFS January 3, 
2017
2024
Table 6. Ongoing adjuvant and neo-adjuvant clinical trials.
Kidney Cancer14
incorporating a genetic recurrence score to evaluate risk of relapse in patients, developing an 
adequate and an objectively standardized adjuvant trial design, identifying novel biomarkers 
and evaluating novel drug targets.
That based on results from current trials, the “high risk for recurrence” RCC patient population 
(T3-T4, grade 3-4) may benefit from adjuvant sunitinib providing DFS advantage but pending 
OS results. Patients, in this category, interested in adjuvant therapy would benefit from a dis-
cussion with an oncologist regarding the potential benefits and risks of adjuvant treatment post 
kidney cancer surgery. Overall, the landscape of adjuvant treatment in nonmetastatic high-risk 
RCC is expected to expand and to further develop in the coming years.
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